Orion Group Holdings Launches Consortium to Strengthen Critical Minerals Supply Chains

Orion Group Holdings Strengthens Supply Chains with New Consortium

Orion Resource Partners LP, a global investment firm specializing in metals and materials, has made a significant move to bolster America’s critical minerals supply chains. On October 23, 2025, the company announces the formation of the Orion Critical Mineral Consortium (Orion CMC), a collaborative initiative aimed at partnering with the U.S. International Development Finance Corporation (DFC) and other leading investors in the metals and mining sectors. This consortium is designed to create secure and resilient supply chains for vital minerals that underpin economic growth and national security for the United States and its allies.

With an initial capital commitment of $1.8 billion and a target of $5 billion, the Orion CMC emphasizes immediate investments in existing or near-term producing assets, rather than long-term exploration projects. This strategic focus is critical as the demand for essential minerals continues to surge, particularly in sectors such as advanced manufacturing and artificial intelligence. Oskar Lewnowski, Founder and CEO of Orion, underscores the importance of this initiative, stating that it represents a significant step in bridging the gap between emerging market nations and global consumers, ultimately addressing the urgent needs for critical minerals in the modern economy.

The consortium's objectives include enhancing domestic processing capabilities and scaling cost-effective technological solutions for mineral extraction and processing. This initiative follows Orion's previous venture, Orion Abu Dhabi, underscoring the company’s commitment to strengthening critical mineral supply chains through strategic partnerships. By prioritizing immediate action and collaboration, Orion CMC places Orion Group Holdings at the forefront of addressing supply chain challenges in the critical minerals sector, which is increasingly vital for sustaining economic and technological progress.

In related developments, Orion Corporation has secured an exclusive commercial license for a monoclonal antibody (mAb) from Abzena, a leading Contract Development and Manufacturing Organization (CDMO). This partnership aims to enhance Orion's oncology-focused research and development pipeline, targeting significant clinical unmet needs. The collaboration leverages Abzena's advanced technologies to ensure optimal outcomes for Orion’s clinical programs, furthering its commitment to innovative healthcare solutions.

Furthermore, as NASA prepares for the Artemis II mission, Orion's involvement in critical minerals supply chains could align with future space exploration needs, showcasing the interconnectedness of resource management and technological advancements across various sectors.